Ensysce Biosciences

ENSC

Biotechnology · Healthcare

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Ensysce Biosciences is a small biotech company focused on developing safer prescription drugs. Its main goal is to create medicines that are harder to abuse — meaning they are designed so people cannot easily misuse or overdose on them. The company's lead programs target opioid painkillers, working to make versions that block the "high" if someone takes too much or tries to snort or inject them.

Ensysce earns money by advancing its drug candidates through clinical trials, with the goal of licensing them to larger pharmaceutical companies or earning royalties once approved. It operates primarily in the United States and is a very small company, with a market cap near zero, meaning it carries significant financial risk. The company's core competitive idea is its proprietary abuse-deterrent technology platform, but its main risk is that it depends heavily on raising outside capital to fund research, and none of its drugs have yet reached commercial approval.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+74.7% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

4.4%ownership

Relatively low insider ownership

Cash Runway

~1 months

$676,704 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Ensysce Biosciences has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

-221.3%

Losing money on operations — -221.3%

Return on the money invested

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-771.2%

Burning cash (-771.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial